Implementing stereotactic arrhythmia radioablation with STOPSTORM.eu consortium support: intermediate results of a prospective Israeli single-institutional trial
The initial results of this trial suggest that STAR can reduce VT episodes in patients with refractory VT without severe adverse effects. The study highlights the importance of international collaboration and standardization in pioneering new treatments. Further follow-up and additional patient data will be necessary to confirm these findings and evaluate long-term outcomes, including potential adjustments to antiarrhythmic medication regimens.
Authors
- Roi Efraim
- Oliver Blanck (ORCID: https://orcid.org/0000-0003-1391-1308)
- Stephan Hohmann (ORCID: https://orcid.org/0000-0002-1606-3423)
- Egor Borzov (ORCID: https://orcid.org/0000-0002-5782-2182)
- Salem Billan
- Jingyang Xie (ORCID: https://orcid.org/0000-0002-1003-0102)
- R. Bar-Deroma (ORCID: https://orcid.org/0000-0003-3398-4221)
- Tomer Charas (ORCID: https://orcid.org/0000-0002-3559-860X)
- Mahmoud Suleiman
Institutions
- Rambam Health Care Campus (IL)
- Medizinische Hochschule Hannover (DE)
- University Hospital Schleswig-Holstein (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Strahlentherapie und Onkologie
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1007/s00066-024-02300-z
- Citations
- 3
- Primary Topic
- Cardiac Arrhythmias and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.21